ClinicalTrials.gg
RecruitingNCT07859722Updated Nov 2, 2026

CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer

An interventional study of Magnetic Resonance Imaging and Questionnaire Administration in Prostate Carcinoma, Stage I Prostate Cancer AJCC v8 and Stage II Prostate Cancer AJCC v8, sponsored by Emory University. Recruiting at 3 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Emory University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 2, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Prostatic Neoplasms by Emory University — 7 open to participants now, 9 under way, 1 of them phase 3. Prostatic Neoplasms · Emory University.

Planned enrollment
5th of 25
100 · median 30
Started
2026
with 1 other
No phase
10 of 25
4 open now
Registered
25th of 25
by date

Among the 25 studies in Prostatic Neoplasms by Emory University, this one is the 5th largest by planned enrollment, is one of 2 that started in 2026, is one of 10 with no phase, and was the 25th registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

7 of the 25 studies in Prostatic Neoplasms by Emory University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Prostatic Neoplasms by Emory University, or all of them as a file.
02

Study summary

This clinical trial studies the safety of a computed tomography (CT) scan, with or without a magnetic resonance imaging (MRI) scan, in planning for high-dose-rate (HDR) prostate brachytherapy treatment in patients with prostate cancer. Brachytherapy is a type of radiation therapy in which radioactive implants, such as pellets, seeds, ribbons, wires, needles, balloons, or capsules, are placed in the body, directly into or near the tumor. The radiation is delivered through a flexible tube called a catheter or a larger device called an applicator. Treatment planning, or simulation, is a process used to plan radiation therapy so that the target area is precisely located and marked. A CT scan is a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body. The pictures are taken from different angles and are used to create 3-dimensional views of tissues and organs. An MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. The addition of MRI to CT for HDR prostate brachytherapy treatment planning may help patients have less urine leakage and less pain after treatment.

Read the detailed description

PRIMARY OBJECTIVE:

I. To compare acute changes in patient reported outcomes of urinary toxicity utilizing the Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain scores for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.

SECONDARY OBJECTIVES:

I. To compare acute and chronic changes in patient reported outcomes of toxicity utilizing the EPIC-26 Urinary Irritative/Obstructive, Bowel, and Sexual domain scores for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.

II. To compare the cumulative incidence of physician reported Common Terminology Criteria for Adverse Events (CTCAE) acute and chronic grade 2+ genitourinary (GU) or gastrointestinal (GI) toxicity for patients undergoing prostate HDR brachytherapy planned with utilization of an MRI versus no MRI.

TERTIARY/EXPLORATORY OBJECTIVE:

I. To compare treatment efficacy for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients undergo treatment planning with a CT scan for HDR brachytherapy.

ARM B: Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy.

After completion of study intervention, patients are followed up at 1, 3, 6, and 12 months.

03

Conditions studied

  • Prostate Carcinoma
  • Stage I Prostate Cancer AJCC v8
  • Stage II Prostate Cancer AJCC v8
  • Stage III Prostate Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men ≥ 18 years old
  • Histopathologically confirmed prostate cancer
  • No evidence of regional or distant
  • Plan to undergo curative-intent HDR brachytherapy with or without external beam radiation therapy

Exclusion criteria

Exclusion Criteria:

  • Prior pelvic radiation therapy
  • No prior prostate MRI
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Arm A (CT, SOC HDR brachytherapy)

    Patients undergo treatment planning with a CT scan for HDR brachytherapy.

    Other: Questionnaire Administration

  • Experimental
    Arm B (CT, MRI, SOC HDR brachytherapy)

    Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy.

    Procedure: Magnetic Resonance Imaging · Other: Questionnaire Administration

Interventions

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI scan

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score

    The primary analysis will be conducted using a mixed-effects model for repeated measures (MMRM) including fixed effects for treatment arm, categorical time, treatment-by-time interaction, baseline Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary incontinence score, age, comorbidity status, and the stratification factors of high-dose-rate treatment approach and rectal spacer use. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother. The primary treatment comparison will be the adjusted between-group difference at the 1-month time point derived from the treatment-by-time interaction using least-squares means, with corresponding two-sided 95% confidence intervals and p-values evaluated at a significance level of 0.05.

    Time frame: At 1 month following treatment

Secondary outcomes

  1. Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score

    Longitudinal analyses of Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary incontinence scores will be conducted using MMRM models analogous to the primary analysis, including the stratification factors as covariates. Adjusted mean scores and between-group differences at each time point will be reported with 95% confidence intervals. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother.

    Time frame: At 3, 6 and 12 months following treatment

  2. Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Irritative/Obstructive, Bowel, and Sexual domain scores

    Longitudinal analyses of Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary irritative/obstructive, bowel, and sexual domain scores will be conducted using MMRM models analogous to the primary analysis, including the stratification factors as covariates. Adjusted mean scores and between-group differences at each time point will be reported with 95% confidence intervals. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother.

    Time frame: At 1, 3, 6 and 12 months following treatment

  3. Cumulative incidence of grade 2 or higher genitourinary or gastrointestinal adverse events

    Will be analyzed using competing-risk methods to account for death as a competing event. Cumulative incidence functions will be estimated for each treatment arm and compared using Gray's test. Fine-Gray subdistribution hazard models, including stratification factors and relevant covariates, will be used to estimate adjusted hazard ratios with 95% confidence intervals. Adverse events will be coded using the Medical Dictionary for Regulatory Activities and graded according to Common Terminology Criteria for Adverse Events version 5.0. Safety analyses will summarize the frequency, severity, and relationship of adverse events to study treatment by System Organ Class and preferred term. Each adverse event will be counted once per participant at the maximum severity grade. Serious adverse events and events leading to treatment discontinuation will be summarized separately.

    Time frame: Within 12 months following treatment

07

Study locations

3 of 3 sites recruiting
08

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for May 2028, 19 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 19 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 6, 2026
StartActual
Oct 22, 2026was Nov 2026
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Emory Proton Therapy Center · Atlanta, United Statesno status→Recruiting
  • Emory University Hospital Midtown · Atlanta, United Statesno status→Recruiting
  • Emory University Hospital/Winship Cancer Institute · Atlanta, United Statesno status→Recruiting
Nov 2, 2026
Start date
Nov 2, 2026→Oct 22, 2026 (actual)
Nov 2, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionMean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score: how it is measured was reworded
Oct 9, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedMean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain scoreTime frame: At 3, 6 and 12 months following treatment
  • EditedMean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Irritative/Obstructive, Bowel, and Sexual domain scoresTime frame: At 1, 3, 6 and 12 months following treatment
Oct 9, 2026
Title
A Randomized Pragmatic Study of CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
Oct 9, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 3 updates
  1. Nov 2, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Emory Proton Therapy Center · Atlanta, United Statesno status→Recruiting
    • Emory University Hospital Midtown · Atlanta, United Statesno status→Recruiting
    • Emory University Hospital/Winship Cancer Institute · Atlanta, United Statesno status→Recruiting
    Start date Nov 2, 2026→Oct 22, 2026 (now actual)
  2. Oct 9, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionMean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score: how it is measured was reworded
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedMean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain scoreTime frame: At 3, 6 and 12 months following treatment
    • EditedMean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Irritative/Obstructive, Bowel, and Sexual domain scoresTime frame: At 1, 3, 6 and 12 months following treatment
    Title A Randomized Pragmatic Study of CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
    + 2 other changes: description and design details
  3. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07859722
Lead sponsor
Emory University
Responsible party
Kamran Salari (Principal Investigator, Emory University) — Principal investigator
First posted
Oct 6, 2026
Start date
Oct 22, 2026
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

Kamran Salari, MD
Contact
kamran.salari@emory.edu
404-686-2391
Sagar Patel, MD
Contact
sagar.patel@emory.edu
404-778-1900
Kamran Salari, MD
principal investigator · Emory University Hospital/Winship Cancer Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion